Compass Pathways’ psilocybin polymorph patent has reached granted, patented-case status at the US patent office, consolidating the intellectual-property position around its synthetic psilocybin, COMP360. The timing is the point. Compass is now in a rolling submission with the FDA, with the final filing targeted for late 2026, which means the patent moat is being reinforced exactly as the product moves from clinical asset toward commercial drug. And the question that has hung over the pharmaceutical-psilocybin business since its inception is about to be tested: how do you own a molecule that humans have used for millennia and that no one can patent?
The problem the patent is built to solve
Psilocybin is a natural compound, known for decades, and the molecule itself is not patentable. Any company trying to build a pharmaceutical business on it therefore has to own something adjacent: the specific crystalline form, the synthesis process, the formulation, or the therapy protocol. Compass’s answer is polymorph protection. It has patented a specific crystalline form of psilocybin, Polymorph A, characterized by a precise X-ray diffraction signature, along with the processes and methods around it. The logic is borrowed directly from small-molecule pharmaceuticals: even after the base compound is in the public domain, owning the exact usable crystalline form can hold back generic competition. COMP360 is the only psilocybin salt form in advanced clinical development, and Compass has layered patents across the form, the synthesis, the dosing method, and the session-based administration protocol.
Why the timing matters
The patent consolidation is not happening in a vacuum. Compass has an FDA rolling review underway for COMP360 in treatment-resistant depression, with final submission targeted for late 2026. And the regulatory weather has turned sharply favorable. On April 18, 2026, the White House issued an executive order titled Accelerating Medical Treatments for Serious Mental Illness, directing the FDA to award Commissioner’s National Priority Vouchers, which compress review toward a one-to-two-month target, to appropriate breakthrough-designated psychedelics, and directing the Justice Department and DEA to begin rescheduling review once a Phase 3 program is complete. Days later the FDA issued three of those vouchers, and COMP360 was one of them, alongside Usona’s psilocybin and Transcend’s methylone. In other words, the pharmaceutical-psilocybin pathway, FDA approval plus DEA rescheduling, is accelerating, and Compass is at the front of the line. That is precisely the moment a patent moat stops being theoretical and starts determining market structure.
The tailwind, and how Compass is using it
The executive order is a genuine macro tailwind, not a rumor, and COMP360’s voucher is real. But it is worth separating what the voucher actually does from what a company’s investor messaging can imply it does. A priority voucher compresses the FDA’s review clock; it does not raise the odds that the review ends in approval. The most relevant precedent makes the distinction vivid: the MDMA program held Breakthrough Therapy designation, the same status that qualifies a drug for these vouchers, and the FDA rejected it anyway in 2024. The order’s language is discretionary, applying to appropriate drugs that meet program criteria, and legal analysts have characterized it as functioning more as a strong political signal than a binding mandate, one that still leaves considerable discretion with the Commissioner, against a backdrop of reports that a psychedelic voucher had been blocked earlier in the year. So the tailwind is real and Compass genuinely benefits from it, but a company still carrying the market’s memory of the Lykos rejection has every incentive to present faster review as though it were likelier approval. Those are not the same thing. The patent moat matters precisely because approval, if it comes, is where the commercial fight actually begins.
How strong is the moat, actually
Here the honest answer is that expert opinion splits. When a nonprofit challenged Compass’s Polymorph A patents, the patent board upheld them, but on narrow grounds: it found that Compass owns that exact crystalline shape, as defined by its specific diffraction measurements, not psilocybin in general. Lawyers for the challengers read that as a real limit, arguing that generic manufacturers have wide latitude to produce psilocybin in forms that are not Polymorph A, and that Compass cannot wield the patents against just any psilocybin medicine. Other patent attorneys read the same ruling as a clean win, noting that competitors will still struggle to guarantee they are not infringing Compass’s forms. Both readings can be partly right. The patent is upheld and real, but bounded, and how much commercial exclusivity it actually buys depends on how hard it proves, in practice, to make and demonstrate a non-infringing crystalline psilocybin. That is an empirical question, and it only gets answered once there is an approved product worth designing around.
What it decides
This is the psilocybin-ownership question coming to a head, and it determines which version of pharmaceutical psilocybin the market gets. If Compass’s polymorph strategy holds, an approved COMP360 enjoys pharma-style exclusivity on a natural compound, and pharmaceutical psilocybin effectively means Compass’s psilocybin for years. If the moat is as porous as the critics claim, competitors and eventually generics erode that exclusivity soon after launch, and pharmaceutical psilocybin becomes a competitive, lower-margin market faster than a conventional new drug would. Either outcome is distinct from the other psilocybin world entirely, the state-regulated, supervised-service model operating in Oregon and Colorado outside the FDA and patent systems altogether. The desk has tracked that bifurcation between the pharmaceutical and regulated-access routes. This patent milestone is the pharmaceutical branch of it hardening into commercial reality.
The caveats
They matter in both directions. The moat’s strength is genuinely contested among patent lawyers, upheld but narrow, so it should be read as neither ironclad nor worthless. Psilocybin itself remains unpatentable, and all the protection sits on adjacent claims, form, process, and method, which are inherently more exposed to design-around than a novel molecule would be. COMP360 is not approved yet; a rolling submission is not a clearance, and the review outcome is pending. Compass’s aggressive and broad patent strategy has already drawn criticism and formal challenges, and more are likely once approval makes the stakes real. And while the favorable regulatory backdrop is real and independently documented, an executive order is a directional signal carried out subject to agency discretion and appropriations, not a guarantee of any particular outcome for any particular drug, and a voucher speeds the review rather than settling it.
The frame
The news is a patent reaching granted status, which sounds procedural. What it actually marks is the pharmaceutical-psilocybin model arriving at its moment of truth. Psilocybin cannot be owned, so Compass has spent years building a fortress around the next best thing, the exact crystalline form, and it is reinforcing that fortress just as COMP360 approaches the FDA and the regulatory path clears. Whether the fortress holds determines whether the first approved psilocybin drug is a protected franchise or the opening of a fast-commoditizing market. The patent office has said Compass owns its shape. The market, and the competitors, will spend the years after approval testing exactly how much that shape is worth. For a compound whose entire mystique is that it is natural, ancient, and freely growing, the decisive commercial question turns out to be intensely technical: whether a particular arrangement of atoms in a crystal, captured by an X-ray fingerprint, can hold back competition long enough to justify the investment. Compass has bet its business that it can, and the approval that would put the bet to the test is now close enough to see.